

## Glyceryl Trinitrate

<b>Form</b>	50mg/10ml ampoule (Glyceryl Trinitrate - Hospira)
<b>Reconstitution</b>	Already in solution Glyceryl trinitrate 50mg in 10 mL <b>must be diluted further before administration.</b>
<b>Compatibility &amp; Stability</b>	Sodium Chloride 0.9% Glucose 5%
<b>Administration</b>	<b>Continuous IV infusion</b> To prepare a <b>1mg/mL</b> solution: Dilute glyceryl trinitrate-Hospira 50mg/10mL by adding each 50mg/10mL ampoule to 40mL of compatible infusion fluid.  Administer via a syringe driver using <b>non-PVC</b> giving set and syringe. If a central venous access device is unavailable, administer via a large peripheral vein monitoring insertion site closely.  Usual max rate of 20mg/hr
<b>Monitoring</b>	<ul style="list-style-type: none"> <li>• Monitor blood pressure and heart rate. Also consider pulmonary capillary wedge pressure, cardiac output</li> </ul>
<b>Extravasation</b>	<ul style="list-style-type: none"> <li>• Extravasation is likely to cause tissue damage due to low pH and presence of excipients propylene glycol and ethanol.</li> </ul>
<b>Additional Information</b>	<ul style="list-style-type: none"> <li>• The diluted solution should be used immediately.</li> <li>• The solution should be clear and colourless to slightly yellow. Do not use if solution is discoloured.</li> <li>• Oral nitrates should be withheld when administering IV.</li> <li>• Glyceryl trinitrate is contraindicated with PDE5 inhibitors such as sildenafil, tadalafil and vardenafil.</li> </ul>

**Information provided relates Glyceryl Trinitrate manufactured by Hospira and Merus Labs**

*This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications. Further information is available from pharmacy on 22142 or 22546.*

*Owner Denise Leamy, Miriam Flynn Pharmacy Department CUH, Version 1 Updated May 2022.*